Document:

<PAGE>

                                                                    Exhibit 10.1

                       3-DIMENSIONAL PHARMACEUTICALS, INC.
                            EQUITY COMPENSATION PLAN
                 (Amended and Restated as of September 17, 1999)

                  The purpose of the Equity Compensation Plan (the "Plan") of
3-Dimensional Pharmaceuticals, Inc. (the "Company") is to promote the interests
of the Company by providing incentives to (i) designated officers and other
employees of the Company or a Subsidiary Corporation (as defined herein), (ii)
non-employee members of the Board of Directors (the "Board") or the Scientific
Advisory Board (the "SAB") of the Company and (iii) independent contractors and
consultants (who may be individuals or entities) who perform services for the
Company, to encourage them to acquire a proprietary interest, or to increase
their proprietary interest, in the Company. The Company believes that the Plan
will cause participants to contribute materially to the growth of the Company,
thereby benefitting the Company's stockholders. For purposes of the Plan, the
terms "Parent Corporation" and "Subsidiary Corporation" shall have the meanings
set forth in subsections (e) and (f) of Section 424 of the Internal Revenue Code
of 1986, as amended (the "Code").

1.   Administration
     --------------

                  The Plan shall be administered and interpreted by the Board or
a committee of the Board consisting of not less than two persons. If the
Company's stock becomes publicly traded in a public offering as described in
Section 16(b) (a "Public Offering"), the Plan shall thereafter be administered
by a committee consisting of "outside directors" under Section 162(m) of the
Code, and the committee may consist of "non-employee directors" as defined under
Rule 16b-3 under the Securities Exchange Act of 1934 (the "Exchange Act") or any
successor provisions. The term "Committee" shall refer to the Board or any
committee designated by the Board pursuant to this Section 1, as the case may
be. The Committee shall have the sole authority to determine (i) who is eligible
to receive Grants (as defined in Section 2 below) under the Plan, (ii) the type,
size and terms of each Grant under the Plan, (iii) the time when each Grant will
be made and the duration of any exercise or restriction period; (iv) any
restrictions on resale applicable to the shares to be issued or transferred
pursuant to the Grant; and (v) any other matters arising under the Plan. The
Committee may, if it so desires, base any of the foregoing determinations upon
the recommendations of management of the Company. The Committee shall have full
power and authority to administer and interpret the Plan and to adopt or amend
such rules, regulations, agreements and instruments as it may deem appropriate
for the proper administration of the Plan. The Committee's interpretations of
the Plan and all determinations made by the Committee pursuant to the powers
vested in it hereunder shall be conclusive and binding on all persons having any
interests in the Plan or in any Grants under the Plan. No person acting under
this subsection shall be held liable for any action or determination made in
good faith with respect to the Plan or any Grant under the Plan.
<PAGE>

2.   Grants
     ------

                  Incentives under the Plan shall consist of Incentive Stock
Options (as defined in Section 5(b) below), Nonqualified Stock Options (as
defined in Section 5(b) below) or Restricted Stock Grants (as defined in Section
6 below) (hereinafter collectively referred to as "Grants"). All Grants shall be
subject to the terms and conditions set forth herein and to such other terms and
conditions of any nature as long as they are not inconsistent with the Plan as
the Committee deems appropriate and specifies in writing to the participant (the
"Grant Letter"). The Committee shall approve the form and provisions of each
Grant Letter. Grants under any section of the Plan need not be uniform as among
the participants receiving the same type of Grant, and Grants under two or more
sections of the Plan may be combined in one Grant Letter.

3.   Shares Subject to the Plan
     --------------------------

                  (a) The aggregate number of shares of the Common Stock, par
value $.001 ("Common Stock"), of the Company that may be issued or transferred
under the Plan is 8,075,000 shares, subject to adjustment pursuant to Section
3(b) below. Such shares may be authorized but unissued shares or reacquired
shares. After a Public Offering, the maximum aggregate number of shares of
Company Stock that shall be subject to Grants made under the Plan to any
individual during any calendar year shall be 1,000,000 shares. If and to the
extent that options granted under the Plan terminate, expire or are canceled
without having been exercised (including shares cancelled as part of an exchange
of Grants), or if any shares of restricted stock are forfeited, the shares
subject to such Grant shall again be available for subsequent Grants under the
Plan.

                  (b) If any change is made to the Common Stock (whether by
reason of merger, consolidation, reorganization, recapitalization, stock
dividend, stock split, combination of shares, or exchange of shares or any other
change in capital structure made without receipt of consideration), then unless
such event or change results in the termination of all outstanding Grants under
the Plan, the Committee shall preserve the value of the outstanding Grants by
adjusting the maximum number and class of shares issuable under the Plan to
reflect the effect of such event or change in the Company's capital structure,
and by making appropriate adjustments to the number and class of shares, the
exercise price of each outstanding option and otherwise, except that any
fractional shares resulting from such adjustments shall be eliminated by
rounding any portion of a share equal to .500 or greater up, and any portion of
a share equal to less than .500 down, in each case to the nearest whole number.

4.   Eligibility for Participation
     -----------------------------

                  Officers and other employees of the Company or a Subsidiary
Corporation, non-employee members of the Board or SAB, and independent
contractors and consultants who perform services for the Company shall be
eligible to participate in the Plan (hereinafter referred to individually as an
"Eligible Participant" and collectively as "Eligible Participants"). Only
Eligible Participants who are officers or other employees of the Company or a
Subsidiary Corporation shall

                                       2
<PAGE>

be eligible to receive Incentive Stock Options. All Eligible Participants shall
be eligible to receive Nonqualified Stock Options and Restricted Stock Grants.
The Committee shall select from among the Eligible Participants those who will
receive Grants (the "Grantees") and shall determine the number of shares of
Common Stock subject to each Grant. The Committee may, if it so desires, base
any such selections or determinations upon the recommendations of management of
the Company. Nothing contained in the Plan shall be construed to limit in any
manner whatsoever the right of the Company to grant rights or options to acquire
Common Stock or awards of Common Stock otherwise than pursuant to the Plan.

5.   Stock Options
     -------------

                  (a)      Number of Shares. The Committee, in its sole
discretion, shall determine the number of shares of Common Stock that will be
subject to each option.

                  (b)      Type of Option and Option Price.

                           (1) The Committee may grant options qualifying as
     incentive stock options within the meaning of Section 422 of the Code
     ("Incentive Stock Options") and other stock options ("Nonqualified Stock
     Options"), in accordance with the terms and conditions set forth herein, or
     may grant any combination of Incentive Stock Options and Nonqualified Stock
     Options (hereinafter referred to collectively as "Stock Options"). The
     option price per share of an Incentive Stock Option shall be the fair
     market value (as defined herein) of a share of Common Stock on the date of
     grant. If the Grantee of an Incentive Stock Option is the owner of Common
     Stock (as determined under section 424(d) of the Code) who possesses more
     than 10% of the total combined voting power of all classes of stock of the
     Company or a Parent Corporation or Subsidiary Corporation, the option price
     per share in the case of an Incentive Stock Option shall not be less than
     110% of the fair market value of a share of Common Stock on the date of
     grant.

                           (2) For all valuation purposes under the Plan, the

     fair market value of a share of Common Stock shall be determined in
     accordance with the following provisions:

                                    (A) If the Common Stock is not at the time
                  listed or admitted to trading on any stock exchange but is
                  traded either on the over-the-counter market or listed on the
                  Nasdaq National Market segment of The Nasdaq Stock Market, the
                  fair market value shall be the closing selling price of one
                  share of Common Stock on the date in question as such price is
                  reported by the NASDAQ system or any successor system. If
                  there is no reported closing selling price for the Common
                  Stock on the date in question, then the closing selling price
                  on the next preceding date for which such quotation exists
                  shall be determinative of fair market value.

                                       3
<PAGE>

                                    (B) If the Common Stock is at the time
                  listed or admitted to trading on any stock exchange, then the
                  fair market value shall be the closing selling price of one
                  share of Common Stock on the date in question on the stock
                  exchange determined by the Committee to be the primary market
                  for the Common Stock, as such prices are officially quoted on
                  such exchange. If there is no reported closing selling price
                  of Common Stock on such exchange on the date in question, then
                  the fair market value shall be the closing selling price on
                  the next preceding date for which such quotation exists.

                                    (C) If the Common Stock is at the time
                  neither listed nor admitted to trading on any stock exchange
                  nor traded in the over-the-counter market (or, if the
                  Committee determines that the value as determined pursuant to
                  Section 5(b)(2)(A) or (B) above does not reflect fair market
                  value), then the Committee shall determine fair market value
                  after taking into account such factors as it deems
                  appropriate.

                  (c) Exercise Period. The Committee shall determine the option
exercise period of each Stock Option. The exercise period shall not exceed ten
years from the date of grant.

                  (d) Vesting of Options and Restrictions on Shares. The vesting
period for Stock Options shall commence on the date of grant (or such date as
may be specified by the Committee) and shall end on the date or dates,
determined by the Committee, that shall be specified in the Grant Letter. The
Committee may impose upon the shares of Common Stock issuable upon the exercise
of a Stock Option such restrictions as it deems appropriate and specifies in the
Grant Letter. During any period in which such restrictions apply, the provisions
of Section 6(d) below shall be applicable to such shares, and the Committee, in
such circumstances as it deems equitable, may determine that all such
restrictions shall lapse.

                  (e) Manner of Exercise. A Grantee may exercise a Stock Option
by delivering a duly completed notice of exercise to the Committee, together
with payment of the option price.

                  (f) Termination of Employment, Disability or Death.

                           (1) If a Grantee ceases to be an Eligible Participant
         for any reason (other than, in the case of an individual, the death of
         such individual) any Stock Option which is otherwise exercisable by the
         Grantee shall terminate unless exercised within three months after the
         date on which the Grantee ceases to be an Eligible Participant (or
         within such other period of time, which may be longer or shorter than
         three months, as may be specified in the Grant Letter), but in any
         event no later than the date of expiration of the option exercise
         period, except that in the case of an individual Grantee who is
         disabled within the meaning of Section 105(d)(4) of the Code, such
         period shall be one year rather than three months (except as otherwise
         provided in the Grant Letter).

                                       4
<PAGE>

                           (2) In the event of the death of an individual
         Grantee while he or she is an Eligible Participant or within not more
         than three months after the date on which the Grantee ceases to be an
         Eligible Participant (or within such other period of time, which may be
         longer or shorter than three months, as may be specified in the Grant
         Letter), any Stock Option which was otherwise exercisable by the
         Grantee at the date of death may be exercised by the Grantee's personal
         representative at any time prior to the expiration of one year from the
         date of death, but in any event no later than the date of expiration of
         the option exercise period.

                  (g) Satisfaction of Option Price. The Grantee shall pay the
option price (i) in cash, (ii) with the consent of the Committee in its sole
discretion, by delivering shares of Common Stock already owned by the Grantee
and having a fair market value on the date of exercise equal to the option price
or a combination of cash and shares of Common Stock, or (iii) in such other
manner as the Committee may designate in the Grant Letter, including without
limitation by tendering the Grantee's recourse promissory note on such terms as
may be specified by the Committee. The Grantee shall pay the option price and
the amount of withholding tax due, if any, at the time of exercise. Shares of
Common Stock shall not be issued or transferred upon any purported exercise of a
Stock Option until the option price and the withholding obligation are fully
paid.

                  (h) Limits on Incentive Stock Options. Each Grant of an
Incentive Stock Option shall provide that:

                      (1)  the Stock Option is not transferable by the Grantee,
         except by will or the laws of descent and distribution;

                      (2)  the Stock Option is exercisable, during the Grantee's
         lifetime, only by the Grantee; and

                      (3)  the aggregate fair market value of the stock on
         the date of the grant with respect to which Incentive Stock Options are
         exercisable for the first time by a Grantee during any calendar year
         under the Plan and under any other stock option plan of the Company and
         its parent and subsidiary corporations shall not exceed $100,000.

6.       Restricted Stock Grants
         -----------------------

                  The Committee may issue shares of Common Stock to an Eligible
Participant on terms approved by the Committee (a "Restricted Stock Grant"). The
following provisions are applicable to Restricted Stock Grants:

                  (a) General Requirements. Shares of Common Stock issued
pursuant to Restricted Stock Grants will be issued in consideration for cash or
services rendered having a value, as determined by the Board, at least equal to
the par value thereof. If Restricted Stock is to be purchased by a Grantee, the
Grantee may pay the purchase price in the form of cash or, if and to the extent
that the Committee so permits, by tendering the Grantee's recourse promissory
note on such

                                       5
<PAGE>

terms as may be specified by the Committee. All conditions and restrictions
imposed under each Restricted Stock Grant, and the period of years during which
the Restricted Stock Grant will remain subject to such restrictions, shall be
set forth in the Grant Letter and designated therein as the "Restriction
Period." All restrictions imposed under any Restricted Stock Grant shall lapse
on such date or dates as the Committee may approve until the restrictions have
lapsed as to 100% of the shares. In addition, the Committee, in circumstances
that it deems equitable, may determine as to any or all Restricted Stock Grants,
that all the restrictions shall lapse, notwithstanding any Restriction Period.

                  (b) Number of Shares. The Committee, in its sole discretion,
shall determine the number of shares of Common Stock that will be granted in
each Restricted Stock Grant.

                  (c) Requirement of Relationship with Company. If the Grantee's
relationship with the Company (as an employee, non-employee member of the Board
or SAB, independent contractor or consultant, as the case may be) terminates
during the period designated in the Grant Letter as the Restriction Period, the
Restricted Stock Grant shall terminate as to all shares covered by the Grant as
to which restrictions on transfer have not lapsed, and such shares shall be
immediately returned to the Company. The Committee may, in its sole discretion,
provide for complete or partial exceptions to the provisions of this Section
6(c).

                  (d) Restrictions on Transfer and Legend on Stock Certificate.
During the Restriction Period, a Grantee may not sell, assign, transfer, pledge
or otherwise dispose of the shares of Common Stock to which such Restriction
Period applies except to a Successor Grantee pursuant to Section 7 below. Each
certificate representing a share of Common Stock issued or transferred under a
Restricted Stock Grant shall contain a legend giving appropriate notice of the
restrictions in the Grant. The Grantee shall be entitled to have the legend
removed from the stock certificate or certificates representing any such shares
as to which all restrictions have lapsed.

7.       Transferability of Options and Grants
         -------------------------------------

                  (a) Except as provided below, only a Grantee (or, in the case
of an individual Grantee, his or her authorized legal representative) may
exercise rights under a Grant. Except as provided below, no individual Grantee
may transfer those rights except by will or by the laws of descent and
distribution. Upon the death of an individual Grantee, the personal
representative or other person entitled to succeed to the rights of the Grantee
("Successor Grantee") may exercise such rights. A Successor Grantee shall
furnish proof satisfactory to the Company of such person's right to receive the
Grant under the Grantee's will or under the applicable laws of descent and
distribution.

                  (b) Transfer of Nonqualified Stock Options. Notwithstanding
the foregoing, the Committee may provide, in a Grant Letter, that a Grantee may
transfer Nonqualified Stock Options to family members or other persons or
entities according to such terms as the Committee may determine, provided that
the transferred Option shall continue to be subject to the same terms and
conditions as were applicable to the Option immediately before the transfer.

                                       6
<PAGE>

8.       Certain Corporate Changes
         -------------------------

                  (a) Sale or Exchange of Assets, Dissolution or Liquidation, or
Merger or Consolidation Where the Company Does Not Survive. If all or
substantially all of the assets of the Company are to be sold or exchanged, the
Company is to be dissolved or liquidated, or the Company is a party to a merger
or consolidation with another corporation in which the Company will not be the
surviving corporation, then, at least ten days prior to the effective date of
such event, the Company shall give each Grantee with any outstanding Grants
written notice of such event. Unless the Committee provides otherwise in the
Grant Letter, each such Grantee shall thereupon have the right to exercise in
full any installments of such Grants not previously exercised (whether or not
the right to exercise such installments has accrued pursuant to such Grants),
within ten days after such written notice is sent by the Company, and any
installments of such Grants not so exercised shall thereafter lapse and be of no
further force or effect.

                  (b) Merger or Consolidation Where the Company Survives. If the
Company is a party to a merger or consolidation in which the Company will be the
surviving corporation, then the Committee may, in its sole discretion, elect to
give each Grantee with any outstanding Grants written notice of such event. If
such notice is given, unless the Committee provides otherwise in the Grant
Letter, each such Grantee shall thereupon have the right to exercise in full any
installments of such Grants not previously exercised (whether or not the right
to exercise such installments has accrued pursuant to such Grants), within ten
days after such written notice is sent by the Company, and any installments of
such Grants not so exercised shall thereafter lapse and be of no further force
or effect.

                  (c) Committee Discretion. Notwithstanding the foregoing, the
Committee may provide in a Grant Letter specific provisions that are applicable
to a Grant in the event of a corporate transaction, and the Committee may also
accelerate the exercisability or vesting of Grants in the event of a corporate
transaction or allow the assumption or substitution of Grants by a surviving
corporation, as the Committee deems appropriate.

9.       Amendment and Termination of the Plan
         -------------------------------------

                  (a) Amendment. The Board may amend or terminate the Plan at
any time; provided, however, that, after a Public Offering, the Board shall not
amend the Plan without shareholder approval if such approval is required by
Section 162(m) of the Code.

                  (b) Termination of Plan. The Plan shall terminate on the tenth
anniversary of its effective date (as set forth in Section 16 below) unless
earlier terminated by the Board or unless extended by the Board with the
approval of the stockholders.

                  (c) Termination and Amendment of Outstanding Grants. A
termination or amendment of the Plan that occurs after a Grant is made shall not
result in the termination or amendment of the Grant unless the Grantee consents
or unless the Committee acts under Section

                                       7
<PAGE>

17(b) below. The termination of the Plan shall not impair the power and
authority of the Committee with respect to an outstanding Grant. Whether or not
the Plan has terminated, an outstanding Grant may be terminated or amended under
Section 17(b) below or may be amended by agreement of the Company and the
Grantee which is consistent with the Plan.

10.      Funding of the Plan
         -------------------

                  The Plan shall be unfunded. The Company shall not be required
to establish any special or separate fund or to make any other segregation of
assets to assure the payment of any Grants under the Plan. In no event shall
interest be paid or accrued on any Grant, including unpaid installments of
Grants.

11.      Rights of Eligible Participants
         -------------------------------

                  Nothing in the Plan shall entitle any Eligible Participant or
other person to any claim or right to any Grant under the Plan. Neither the Plan
nor any action taken hereunder shall be construed as giving any Eligible
Participant or Grantee any rights to be retained by the Company in any capacity,
whether as an employee, non-employee member of the Board or SAB, independent
contractor, consultant or otherwise.

12.      Withholding of Taxes
         --------------------

                  The Company shall have the right to deduct from all Grants
paid in cash any federal, state or local taxes required by law to be withheld
with respect to such Grants paid in cash. In the case of Grants paid in Common
Stock, the Company shall have the right to require the Grantee to pay to the
Company the amount of any taxes which the Company is required to withhold in
respect of such Grants or to take whatever action it deems necessary to protect
the interests of the Company in respect of such tax liabilities, including,
without limitation, withholding a portion of the shares of Common Stock
otherwise deliverable pursuant to the Plan. The Company's obligation to issue or
transfer shares of Common Stock upon the exercise of a Stock Option or the
acceptance of a Restricted Stock Grant shall be conditioned upon the Grantee's
compliance with the requirements of this section to the satisfaction of the
Committee.

13.      Agreements with Grantees
         ------------------------

                  Each Grant made under the Plan shall be evidenced by a Grant
Letter containing such terms and conditions as the Committee shall approve.

14.      Requirements for Issuance of Shares
         -----------------------------------

                  No Common Stock shall be issued or transferred under the Plan
unless and until all applicable legal requirements have been complied with to
the satisfaction of the Committee. The Committee shall have the right to
condition any Stock Option or Restricted Stock Grant on the

                                       8
<PAGE>

Grantee's undertaking in writing to comply with such restrictions on any
subsequent disposition of the shares of Common Stock issued or transferred
thereunder as the Committee shall deem necessary or advisable as a result of any
applicable law, regulation or official interpretation thereof, and certificates
representing such shares may be legended to reflect any such restrictions.

15.      Headings
         --------

                  The section headings of the Plan are for reference only. In
the event of a conflict between a section heading and the content of a section
of the Plan, the content of the section shall control.

16.      Effective Dates
         ---------------

                  (a) Effective Date of the Plan.  The Plan was originally
effective as of August 31, 1993.

                  (b) Public Offering. The provisions of the Plan that refer to
a Public Offering, or that refer to, or are applicable to persons subject to,
Section 16 of the Exchange Act or Section 162(m) of the Code, shall be
effective, if at all, upon the initial registration of Common Stock under
Section 12(g) of the Exchange Act, and shall remain effective thereafter for so
long as such Stock is registered.

17.      Miscellaneous
         -------------

                  (a) Substitute Grants. The Committee may make a Grant to an
employee, a non-employee director, or an independent contractor or consultant of
another corporation, if such person shall become an Eligible Participant by
reason of a corporate merger, consolidation, acquisition of stock or property,
reorganization or liquidation involving the Company or a Subsidiary Corporation
and such other corporation. Any such Grant shall be made in substitution for a
stock option or restricted stock grant granted by the other corporation
("Substituted Stock Incentives"), but the terms and conditions of the substitute
Grant may vary from the terms and conditions required by the Plan and from those
of the Substituted Stock Incentives. The Committee shall prescribe the
provisions of the substitute Grants.

                  (b) Compliance with Law. The Plan, the exercise of Grants and
the obligations of the Company to issue or transfer shares of Common Stock under
Grants shall be subject to all applicable laws and required approvals by any
governmental or regulatory agencies. With respect to persons subject to Section
16 of the Exchange Act, it is the intent of the Company that the Plan and all
transactions under the Plan shall comply with all applicable conditions of Rule
16b-3 or any successor provisions under the Exchange Act. The Committee may
revoke any Grant if it is contrary to law or modify any Grant to bring it into
compliance with any valid and mandatory government regulations. The Committee
may also adopt rules regarding the withholding of taxes on payments to Grantees.
The Committee may, in its sole discretion, agree to limit its authority under
this section.

                                       9
<PAGE>

                  (c) Ownership of Stock. A Grantee or Successor Grantee shall
have no rights as a stockholder with respect to any shares of Common Stock
covered by a Grant until the shares are issued or transferred to the Grantee or
Successor Grantee on the stock transfer records of the Company.

                                       10
<PAGE>

                                                                    Exhibit 10.1
                                                             Amendment to Equity
                                                               Compensation Plan

                      3-DIMENSIONAL PHARMACEUTICALS, INC.

                            Secretary's Certificate
                            -----------------------

                                March 31, 2000

          I, Scott M. Horvitz, do hereby certify that I am the Secretary of 3-
Dimensional Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and
that, as such, I am authorized to execute this certificate on behalf of the
Company and do further certify that:

          1.    Attached hereto as Exhibit A is a true and correct copy of all
resolutions of the Board of Directors of the Company relating to the
transactions contemplated by the Series A-5 Preferred Stock Purchase Agreement
(the "Agreement"), dated March 31, 20000 (the "Agreement"), between the Company
and the Buyers as defined in the Agreement. All of the resolutions contained in
Exhibit A were duly adopted at a special telephonic meeting of the Board of
Directors of the Company held on March 30, 2000, none of such resolutions has
been rescinded or amended in any respect, and all are in full force and effect
on the date hereof.

          2.    Attached hereto as Exhibit B is a true and correct copy of all
resolutions of the stockholders of the Company relating to the transactions
contemplated by the Agreement. The resolutions contained in Exhibit B were duly
adopted by Consent of Series B Preferred, Series C Preferred and Common
Stockholders of the Company dated March 31, 2000 and by Consent of Series A-1,
Series A-2, Series A-3 and Series A-4 Preferred Stockholders of the Company
dated March 31, 2000, respectively, none of such resolutions has been rescinded
or amended in any respect, and all are in full force and effect on the date
hereof.

          3.    A certified copy of the Sixth Restated Certificate of
Incorporation of the Company (the "Certificate of Incorporation") is attached
hereto as Exhibit C.

          4.    Attached hereto as Exhibit D is a true and correct copy of the
Bylaws of the Company, which are in full force and effect on the date hereof.

          IN WITNESS WHEREOF, I have hereunto set my hand on the date first set
forth above.

                                    /s/ Scott M. Horvitz
                                    ------------------------------
                                    Scott M. Horvitz
                                    Secretary
<PAGE>

                                                                   Exhibit A

                      3-DIMENSIONAL PHARMACEUTICALS, INC.
                 RESOLUTIONS ADOPTED BY THE BOARD OF DIRECTORS

Equity Compensation Plan and Amendment and Restatement of Restated Certificate
-----------------------------------------------------------------------------
of Incorporation
----------------

          RESOLVED, that an amendment to the Amended and Restated Equity
     Compensation Plan of the Company (the "Plan") increasing by 1,250,000
     shares the number of shares of Common Stock that may be issued or
     transferred under the Plan and the grant of 750,000 options to employees
     and consultants of the Company (the "Plan Amendment") is hereby approved
     and adopted; and it is further

          RESOLVED, that the Board of Directors hereby proposes and deems
     it advisable that the Company's Fifth Restated Certificate of
     Incorporation, (the "Restated Certificate"), be amended and restated in its
     entirety as set forth in the Sixth Restated Certificate of Incorporation
     attached as Exhibit A hereto (the "Amendment and Restatement") (as so
                 ---------
     amended, the "Amended and Restated Certificate"); and it is further

          RESOLVED, that the officers of the Company be and they are
     hereby authorized and directed to submit the Plan Amendment and the
     Amendment and Restatement for consideration by the stockholders entitled to
     vote in respect thereof; and it is further

          RESOLVED, that upon the approval of the Plan Amendment and the
     Amendment and Restatement by the stockholders in accordance with Section
     242 of the Delaware General Corporation Law, the proper officers of the
     Company be and they are hereby authorized and directed to prepare, execute
     and file the Amended and Restated Certificate with the Secretary of State
     of the State of Delaware.<PAGE>

                                                                    EXHIBIT 10.5

                   SERIES D PREFERRED STOCK PURCHASE AGREEMENT

     This Series D Preferred Stock Purchase Agreement (the "Agreement") is
entered into as of May 17, 2000 by and between 3-Dimensional Pharmaceuticals,
Inc., a Delaware corporation, having its principal place of business at
Eagleview Corporate Center, 665 Stockton Drive, Suite 104, Exton, Pennsylvania
19341 ("3-DP"), and Schering Berlin Venture Corporation, a Delaware corporation,
having its principal place of business at 340 Changebridge Road, Montville, New
Jersey 07058 ("Schering").

                                   Background
                                   ----------

     3-DP and Schering AG, a company organized and existing under the laws of
the Federal Republic of Germany, having its principal place of business at 13342
Berlin, Germany ("Schering AG") have entered into a License and Research
Agreement (the "License Agreement") dated as of the date hereof. In connection
with the License Agreement, Schering AG has agreed to make the Stock Purchase
(as defined below) through its affiliate, Schering. This Agreement sets forth
the agreement of 3-DP and Schering with respect to the Stock Purchase. Certain
defined terms used herein and not defined herein shall have the respective
meanings given to such terms in the License Agreement.

                                   Witnesseth:
                                   ----------

     In consideration of the representations and covenants and obligations
expressed herein, and intending to be legally bound, the parties agree as
follows:

1.   Definitions. As used in this Agreement, the following terms have the
     -----------
meanings specified or referred to in this Section 1.

     "Business Day" means any day that is not a Saturday or Sunday or a day
      ------------
on which banks located in the City of New York, New York are authorized or
required to be closed.

     "Certificate of Incorporation" means the Restated Certificate, as amended
      ----------------------------
from time to time.

     "Closing" shall have the meaning set forth in Section 3.
      -------

     "Closing Date" shall have the meaning set forth in Section 3.
      ------------

     "Commission" means the U.S. Securities and Exchange Commission.
      ----------

     "Common Stock" means the common stock, par value $.001 per share, of 3-DP.
      ------------
<PAGE>

     "Conversion Shares" means the shares of Common Stock issuable upon
      -----------------
conversion of the Series D Preferred Shares.

     "Exchange Act" means the Securities Exchange Act of 1934, as amended.
      ------------

     "IPO" means 3-DP's initial distribution of Common Stock for cash in a firm
      ---
commitment underwritten public offering to the general public pursuant to a
registration statement filed with and declared effective by the Commission
pursuant to the Securities Act.

     "IPO Effective Date" means the date upon which the IPO Registration
      ------------------
Statement is declared effective by the Commission.

     "IPO Registration Statement" means the registration statement filed by 3-DP
      --------------------------
with the Commission to register the Common Stock to be sold in the IPO.

     "Material Adverse Effect" shall have the meaning set forth in Section 4.1.
      -----------------------

     "NASDAQ" shall mean the National Association of Securities Dealers
      ------
Automated Quotations System.

     "Preferential Registration Rights" shall have the meaning set forth in
      --------------------------------
Section 6.3.1.

     "Registrable Securities" means the Conversion Shares as adjusted for stock
      ----------------------
splits, stock dividends, combinations and others recapitalizations.

     "Restated Certificate" shall have the meaning set forth in Section 2.1.
      --------------------

     "Securities" means the Series D Preferred Shares and the Conversion Shares.
      ----------

     "Securities Act" means the Securities Act of 1933, as amended.
      --------------

     "Series D Preferred Shares" means the shares of Series D Preferred Stock
      -------------------------
issued and issuable pursuant to the terms of this Agreement and the Certificate
of Incorporation.

     "Series D Preferred Stock" means the Series D preferred stock, par value
      ------------------------
$.001 per share, of 3-DP.

     "Stockholders' Agreement" means the Amended and Restated Stockholders'
      -----------------------
Agreement dated as of March 31, 2000 among 3-DP and certain stockholders of
3-DP.

     "Stock Purchase" shall have the meaning set forth in Section 2.2.
      --------------

2.   Authorization and Purchases and Sales of Series D Preferred Stock.

                                       2
<PAGE>

     2.1 Authorization. The Series D Preferred Stock to be issued or issuable to
         -------------
Schering hereunder shall have the voting powers, dividend rights, liquidation
rights, designations, preferences and relative, participating, optional or other
special rights, and the qualifications, limitations and restrictions thereof,
set forth in 3-DP's Seventh Restated Certificate of Incorporation in the form of
Exhibit 2.1 attached hereto and incorporated herein (the "Restated
-----------
Certificate").

     2.2 Stock Purchase. Subject to the terms and conditions hereof, at the
         --------------
Closing, (i) Schering will purchase from 3-DP and 3-DP will sell to Schering,
625,000 Series D Preferred Shares at a purchase price of $8.00 per share for an
aggregate purchase price of $5,000,000 (the "Stock Purchase"), payable by
Schering by wire transfer in immediately available funds to the account of 3-DP,
and (ii) 3-DP will deliver or cause to be delivered to Schering a duly executed
certificate representing the Series D Preferred Shares in proper form for
transfer, with appropriate transfer stamps, if any, affixed.

3.   Closing. The closing (the "Closing") of the Stock Purchase shall be held at
     -------
the offices of Morgan, Lewis & Bockius LLP, 1701 Market Street, Philadelphia,
Pennsylvania, on May 17, 2000, or, if the conditions to the Closing set forth in
Articles 9 and 10 shall not have been satisfied by such date, as soon as
practicable after such conditions shall have been satisfied. The date on which
the Closing shall occur is hereinafter referred to as the "Closing Date".

4.   Representations and Warranties of 3-DP. 3-DP represents and warrants to
     --------------------------------------
Schering as of the date hereof and as of the Closing Date as follows:

     4.1 Organization and Standing. 3-DP has been duly incorporated and is
         -------------------------
validly existing as a corporation in good standing under the laws of the State
of Delaware and has all requisite corporate power and authority to carry on its
business as now conducted. 3-DP is duly qualified to transact business and is in
good standing in each jurisdiction in which the failure so to qualify would be
reasonably expected to have a material adverse effect on the business,
operations, properties, assets, prospects or condition (financial or otherwise)
of 3-DP (a "Material Adverse Effect").

     4.2 Corporate Power; Authorization. 3-DP has all requisite legal and
         ------------------------------
corporate power and has taken all requisite corporate action to execute and
deliver this Agreement, to sell and issue the Securities and to carry out and
perform all of its obligations hereunder. This Agreement has been duly
authorized, executed and delivered on behalf of 3-DP and constitutes the legal,
valid and binding agreement of 3-DP, enforceable in accordance with its terms,
except (i) as limited by applicable bankruptcy, insolvency, reorganization or
similar laws relating to or affecting the enforcement of creditors' rights
generally, (ii) as limited by equitable principles generally and (iii) rights to
indemnification and contribution hereunder may be limited by applicable law. The
consummation of the transactions contemplated herein and the fulfillment of the
terms hereof will not result in a breach of any of the terms or provisions of,
or constitute a default under, any license, any judgment, order or decree or
statute, law, ordinance, rule or regulation applicable to 3-DP or its properties
or assets, 3-DP's Certificate of Incorporation or 3-

                                       3
<PAGE>

DP's bylaws except such terms or provisions as will have been waived prior to
the Closing. In addition, the consummation of the transactions contemplated
herein and the fulfillment of the terms hereof will not result in a breach of
any of the terms or provisions of, or constitute a default under, any indenture,
mortgage, deed of trust or other agreement or instrument to which 3-DP is a
party or by which it is bound other than any such items that, individually or in
the aggregate would not have a Material Adverse Effect and except such terms or
provisions as will have been waived prior to the Closing .

     4.3 Capitalization. As of the Closing Date, the authorized capital stock of
         --------------
3-DP is 97,994,126 shares, consisting of 6,926,461 shares of Series A-1
Preferred Stock, 4,333,990 shares of Series A-2 Preferred Stock, 10,304,264
shares of Series A-3 Preferred Stock, 4,000,000 shares of Series A-4 Preferred
Stock, 9,572,248 shares of Series A-5 Preferred Stock, 1,000,000 shares of
Series B Preferred Stock, 5,000,000 shares of Series C Preferred Stock, 625,000
shares of Series D Preferred Stock and 56,232,163 shares of Common Stock. As of
the Closing Date, 6,686,986 shares of Series A-1 Preferred Stock were issued and
outstanding, 4,333,990 shares of Series A-2 Preferred Stock were issued and
outstanding, 10,304,264 shares of Series A-3 Preferred Stock were issued and
outstanding, 4,000,000 shares of Series A-4 Preferred Stock were issued and
outstanding, 9,572,248 shares of Series A-5 Preferred Stock were issued and
outstanding, 1,000,000 shares of Series B Preferred Stock were issued and
outstanding, 400,000 shares of Series C Preferred Stock were issued and
outstanding, 625,000 shares of Series D Preferred Stock were issued and
outstanding and 2,645,881 shares of Common Stock were issued and outstanding.
Except as disclosed in Schedule 4.3 and except for the transactions expressly
                       ------------
contemplated hereby, since March 31, 2000, 3-DP has not issued any shares of
Common Stock or Series D Preferred Stock, granted any options or issued
restricted stock (except for stock options granted and restricted stock issued
under 3-DP's employee, consultant and director stock option plans), warrants,
rights (including conversion or preemptive rights, except for stock purchased
under 3-DP's stock purchase plans), or similar rights to any person or entity to
purchase or acquire any rights with respect to any shares of capital stock of
3-DP. The outstanding shares of Series A-1 Preferred Stock, Series A-2 Preferred
Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series A-5
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D
Preferred Stock and Common Stock have been duly authorized and validly issued
and are fully paid and nonassessable; and none of such outstanding shares was
issued in violation of the preemptive rights, purchase option, call, right of
first refusal or similar rights, if any, of any stockholder of 3-DP.

          4.3.1.(a) Securities; Conversion Shares. 3-DP has full corporate power
                    -----------------------------
and authority to sell the Securities on the terms and conditions contemplated
herein, and when so sold against payment therefor as provided herein, the
Securities will be validly authorized and issued, fully paid and nonassessable
and will have the rights, preferences and privileges described in the
Certificate of Incorporation and, assuming the accuracy of Schering's
representations and warranties contained in Section 5.1 and 5.2, will be issued
in compliance with all applicable federal and state securities laws. The
issuance and delivery of the Securities is not subject to preemptive or any
similar rights of any stockholders of 3-DP or any liens or

                                       4
<PAGE>

encumbrances arising through 3-DP, except such preemptive or similar rights as
will have been waived prior to the Closing hereunder; and when the Conversion
Shares are issued in accordance with the Certificate of Incorporation, they will
be validly issued and outstanding, fully paid and nonassessable and free of any
liens or encumbrances arising through 3-DP or any of its affiliates and will be
issued in compliance with all applicable federal and state securities laws.

          4.3.1.(b) Subsidiaries. Except as set forth on Schedule 4.3.1.(b),
                    ------------                         ------------------
3-DP does not currently own or control, directly or indirectly, any interest in
any other corporation, partnership, association or other business entity, and
3-DP is not a member of or participant in any partnership, joint venture or
similar person.

     4.4 Compliance with Other Instruments. The execution, delivery and
         ---------------------------------
performance of this Agreement and of the transactions contemplated hereby will
not result in a breach of any of the terms or provisions of, or constitute a
default under, any license, any judgment, order or decree or statute, law,
ordinance, rule or regulation applicable to 3-DP or its properties or assets,
3-DP's Certificate of Incorporation or 3-DP's bylaws except such terms or
provisions as will have been waived prior to the Closing. In addition, the
consummation of the transactions contemplated herein and the fulfillment of the
terms hereof will not result in a breach of any of the terms or provisions of,
or constitute a default under, any indenture, mortgage, deed of trust or other
agreement or instrument to which 3-DP is a party or by which it is bound other
than any such items that, individually or in the aggregate would not have a
Material Adverse Effect and except such terms or provisions as will have been
waived prior to the Closing .

     4.5 Governmental Consents. Except as set forth in Schedule 4.5, no consent,
         ---------------------                         ------------
approval, license, permit, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or
local governmental authority is required on the part of 3-DP in connection with
3-DP's valid execution, delivery and performance of this Agreement. The filings
under state securities laws, if any, will be effected by 3-DP at its cost within
the applicable stipulated statutory period.

     4.6 Financial Statements. Attached hereto as Schedule 4.6 are year-end
         --------------------                     ------------
audited financial statements of 3-DP for the fiscal year ended December 31, 1998
and year-end unaudited financial statements of 3-DP for the fiscal year ended
December 31, 1999 (the "Financial Statements"). The Financial Statements have
been prepared in accordance with generally accepted accounting principles
applied on a consistent basis throughout the periods indicated therein, except
as may be indicated therein or in the notes thereto, and fairly present the
financial condition of 3-DP as of the respective dates thereof and the results
of its operations and statements of cash flows for the periods then ended,
subject, in the case of unaudited financial statements, to normal year-end
adjustments. Except as reflected in the Financial Statements, 3-DP has no
liabilities or obligations of any nature, whether absolute, contingent or
accrued, unasserted or otherwise, that would have a Material Adverse Effect.

     4.7 Absence of Certain Changes. Except as set forth in Schedule 4.7, since
         --------------------------                         ------------
December 31, 1999, there has been no:

                                       5
<PAGE>

          4.7.1 change in the business, operations, properties, assets,
prospects or condition (financial or otherwise) of 3-DP, except changes in the
ordinary course of business that have not, individually or in the aggregate,
resulted in and are not reasonably expected to result in a Material Adverse
Effect;

          4.7.2 damage, destruction or loss, whether or not covered by
insurance, materially and adversely affecting the business, properties or
financial condition of 3-DP;

          4.7.3 waiver or compromise by 3-DP of a material right or of a
material debt owed to it;

          4.7.4 satisfaction or discharge of any lien, claim or encumbrance by
3-DP, except in the ordinary course of business and which is not material to the
business, properties or financial condition of 3-DP;

          4.7.5 material change to a material contract or arrangement by which
3-DP or any of its assets is bound or subject;

          4.7.6 sale, assignment or transfer to a third party of any material
patents, trademarks, copyrights, trade secrets or other intangible assets for
compensation which is less than fair value;

          4.7.7 mortgage, pledge, transfer of a security interest in, or lien,
created by 3-DP, with respect to any of its material properties or assets,
except liens for taxes not yet due or payable; or

          4.7.8 declaration, setting aside or payment or other distribution in
respect of any of 3-DP's capital stock.

     4.8  Contracts. 3-DP is not, and has no actual knowledge that any other
          ---------
party is, in default under or in respect of any contract, commitment or
agreement to which 3-DP is a party or by which any of its assets or properties
are bound, the result of which default would be reasonably expected to have a
Material Adverse Effect. No party to any contract, commitment or agreement would
be authorized or permitted to terminate its obligations thereunder by reason of
the execution and delivery of this Agreement or any of the transactions
contemplated herein, except with respect to such terms and conditions thereof as
shall have been waived prior to the Closing.

     4.9  Compliance. 3-DP has complied with, and is not in default under or in
          ----------
violation of, its Certificate of Incorporation, bylaws or any law, statute,
ordinance, rule or regulation or other governmental restriction, order, judgment
or decree directly applicable to 3-DP, except where the failure to comply or any
such default or violation would not be reasonably expected to have a Material
Adverse Effect. 3-DP has not received notice of any possible or actual violation
of any applicable law, statute, ordinance, rule, regulation or other
governmental restriction, order,

                                       6
<PAGE>

judgment or decree the result of which violation would be reasonably expected to
have a Material Adverse Effect.

     4.10 Litigation. Except as set forth in Schedule 4.10, there is no action,
          ----------                         -------------
suit, proceeding or investigation pending or, to 3-DP's knowledge, currently
threatened against 3-DP which questions the validity of this Agreement or the
right of 3-DP to enter into this Agreement or to consummate the transactions
contemplated hereby. There is no action, suit, proceeding or investigation
pending or, to 3-DP's knowledge, currently threatened against 3-DP, which
individually or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would be reasonably expected to have a Material Adverse
Effect.

     4.11 Permits. 3-DP has complied with, and is not in default in any respect
          -------
under, all governmental franchises, permits, licenses, and any similar authority
necessary for the conduct of its business as now being conducted by it, except
where the failure to so comply or such default would not be reasonably expected
to have a Material Adverse Effect.

     4.12 Taxes. 3-DP has filed all federal, state and other tax returns which
          -----
are required to be filed and has heretofore paid all taxes which have become due
and payable, except where the failure to file or pay would not be reasonably
expected to have a Material Adverse Effect. The provision for taxes on the
balance sheet as of December 31, 1999 is sufficient for the payment of all
material accrued and unpaid taxes of 3-DP with respect to the period then ended.

     4.13 Title. 3-DP owns no real properties. 3-DP has good and valid title to
          -----
all other properties (personal and mixed, tangible and intangible) that it
purports to own and a valid leasehold interest in all properties that it has
leased.

     4.14 Intellectual Property. Except as set forth in Schedule 4.14(a), to the
          ---------------------                         ----------------
knowledge of 3-DP and in 3-DP's reasonable opinion, 3-DP owns, or possesses
adequate rights to use, all of its patents, patent rights, trademarks, trade
secrets, know-how and proprietary techniques (including processes and
substances, service marks, trade names and copyrights) owned or used by it in
the conduct of its business as presently conducted, except where the failure to
own or possess such patents, patent rights, trademarks, trade secrets, know-how
or proprietary techniques would not be reasonably expected to have a Material
Adverse Effect. Except as set forth in Schedule 4.14(b), 3-DP has not received
                                       ----------------
any notice of infringement of or conflict with asserted rights of others with
respect to any patents, patent rights, trademarks, trade secrets, know-how or
proprietary techniques which, singly or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, would be reasonably expected to have a
Material Adverse Effect.

     4.15 Investment Company Act. 3-DP is not an "investment company" within the
          ----------------------
meaning of the Investment Company Act of 1940, as amended.

5.   Representations and Warranties of Schering. Schering represents and
     ------------------------------------------
warrants to 3-DP as of the date hereof and as of the Closing Date as follows:

                                       7
<PAGE>

     5.1 Investment Representations. Schering has had an opportunity to ask
         --------------------------
questions, review documents and gather information about 3-DP and, based upon
such information and the representations and warranties made herein being true
and correct in all material respects, has acquired sufficient information about
3-DP to reach an informed and knowledgeable decision to acquire the Series D
Preferred Shares. Schering has such business and financial experience as is
required to give it the capacity to protect its own interests in connection with
the purchase of the Series D Preferred Shares. Schering is an "accredited
investor" as defined in Rule 501(a) under the Securities Act.

     5.2 Investment Intent. Schering is acquiring the Securities for investment
         -----------------
for its own account only and not with a view to, or for resale in connection
with, any "distribution" thereof within the meaning of the Securities Act.
Schering understands that the Securities have not been registered under the
Securities Act or registered or qualified under any state securities law in
reliance on specific exemptions therefrom, which exemptions may depend upon,
among other things, the bona fide nature of Schering's investment intent as
expressed herein. Schering is familiar with Rule 144 under the Securities Act,
as presently in effect, and understands the resale limitations imposed thereby
and by the Securities Act.

     5.3 No Legal, Tax or Investment Advice. Schering understands that nothing
         ----------------------------------
in this Agreement or any other materials presented to Schering in connection
with the acquisition and sale of the Securities constitutes legal, tax or
investment advice. Schering has consulted such legal, tax and investment
advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its acquisition of the Securities.

     5.4 Corporate Power; Authority. Schering has all requisite legal and
         --------------------------
corporate power and has taken all requisite corporate action to execute, deliver
and perform it obligations under this Agreement. This Agreement has been duly
authorized, executed and delivered on behalf of Schering and constitutes the
legal, valid and binding agreement of Schering, enforceable in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization or similar laws relating to or affecting the enforcement of
creditors' rights generally, (ii) as limited by equitable principles generally
and (iii) rights to indemnification and contribution hereunder may be limited by
applicable law.

6.   Restrictions on Transfer and Registration Rights.
     ------------------------------------------------

     6.1 Restrictions on Transferability. The Securities shall not be
         -------------------------------
transferable in the absence of a registration under the Securities Act or an
exemption therefrom or in the absence of compliance with any term of this
Agreement. 3-DP shall be entitled to give stop transfer instructions to the
transfer agent with respect to the Securities in order to enforce the foregoing
restrictions. The following provisions shall govern the transfer of the
Securities (except if the transferred Securities are freely tradable pursuant to
an effective registration statement or Rule 144):

                                       8
<PAGE>

          6.1.1 Schering, and Schering shall require that any other holder of
any Securities by acceptance thereof, agrees that, prior to any such transfer of
any Securities, such holder will give written notice to 3-DP of such holder's
intention to effect such transfer and to comply in all other respects with the
provisions of this Section 6.1. Unless waived by 3-DP and unless the related
transfer is to an entity that directly or indirectly controls or is controlled
by or under common control with the holder, each such notice shall be
accompanied by an opinion of counsel for such holder (who may be the inside or
staff counsel employed by such holder), stating that registration under the
Securities Act and applicable state securities laws in connection with such
transfer is not required and stating the factual and statutory bases relied upon
by counsel. The following provisions shall then apply:

               6.1.1.(a) If in the opinion of counsel for 3-DP the proposed
transfer of such Securities may be effected without registration or
qualification under the Securities Act and any applicable state securities laws,
then the registered holder of such Securities shall be entitled to transfer such
Securities in accordance with the intended method of disposition specified in
the statement delivered by such holder to 3-DP.

               6.1.1.(b) If in the opinion of counsel for 3-DP the proposed
transfer of such Securities may not be effected without registration under the
Securities Act or registration or qualification under any applicable state
securities laws, the registered holder of such Securities shall not be entitled
to transfer such Securities until the requisite registration or qualification is
effective.

               6.1.1.(c) If Securities are sold or otherwise transferred
hereunder with the restrictive legends thereon, any such transferee of such
Securities shall agree in writing to be bound by the restrictions on transfer
set forth in this Section 6 prior to the transfer of the Securities.

          6.1.2 Each certificate evidencing the Securities issued upon such
transfer (and each certificate evidencing any untransferred balance of such
Securities) shall bear the legend set forth in Section 6.2 hereof unless (i) in
the opinion of counsel (reasonably acceptable to 3-DP) addressed to 3-DP the
registration of future transfers is not required by the applicable provisions of
the Securities Act or applicable state securities laws; (ii) 3-DP shall have
waived the requirement of such legend; or (iii) in the opinion of counsel to
3-DP, such transfer shall have been made in connection with an effective
registration statement filed pursuant to the Securities Act or in compliance
with the requirements of Rule 144 or Rule 144A (or similar or successor rule)
promulgated under the Securities Act, and in compliance with applicable state
securities laws.

     6.2  Restrictive Legends.
          -------------------

          6.2.1 Each certificate representing Securities shall bear
substantially the following legend (in addition to any legends required under
applicable securities laws):

                                       9
<PAGE>

          THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR
          INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
          1933. THE SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH
          REGISTRATION OR AN EXEMPTION THEREFROM, PURSUANT TO CERTAIN PROCEDURES
          SET FORTH IN THE SERIES D PREFERRED STOCK PURCHASE AGREEMENT BETWEEN
          THE ORIGINAL PURCHASER AND 3-DP (COPIES OF WHICH MAY BE OBTAINED FROM
          3-DP).

          6.2.2 Whenever such restrictions on transfer pursuant to this Section
6 shall terminate, Schering shall be entitled to receive from 3-DP without
expense a new certificate or certificates for the Securities not bearing the
legends set forth in this Section 6.

     6.3  Registration of Securities.
          --------------------------

          6.3.1 Demand Registration. Subject to the preferential registration
                -------------------
rights of the holders of Series A Preferred Stock set forth in the Stockholders'
Agreement attached hereto as Exhibit 6.3.1, as the same may be amended from time
                             -------------
to time (the "Preferential Registration Rights"), Schering will have the right,
on one occasion after the expiration of 12 calendar months after the IPO
Effective Date, to require 3-DP to file a registration statement (the "Demand
Registration Statement") with the Commission under the Securities Act to
register the resale of the Registerable Securities. 3-DP shall use its best
efforts to promptly effect the registration under the Securities Act of all the
Registerable Securities that Schering requests to be registered. The Company
shall not be obligated to file and cause to become effective any Demand
Registration Statement within a period not to exceed four months after the date
of a request for registration pursuant to this Section 6.3.1 if, at the time of
such request, the filing of such Demand Registration Statement would, as
determined in good faith by a majority of the Board, be seriously detrimental to
3-DP or its stockholders or adversely affect a material financing project or a
material proposed or pending acquisition, merger or other similar corporate
transaction to which 3-DP is or imminently expects to be a party, in which case
registration shall take place as soon as practicable thereafter.

          6.3.2 S-3 Registrations. Subject to the Preferential Registration
                -----------------
Rights, Schering will have the right, at any time after the expiration of 12
calendar months after the IPO Effective Date, to require 3-DP to file one or
more shelf registration statements on Form S-3 (each, a "Form S-3 Registration
Statement") with the Commission under the Securities Act to register for resale
the Registerable Securities in an underwritten transaction. 3-DP shall use its
best efforts to promptly effect the registration under the Securities Act of all
the Registerable Securities that Schering requests to be registered. The Company
shall not be obligated to file and cause to become effective any Form S-3
Registration Statement within a period not to exceed four months after the date
of a request for registration pursuant to this Section 6.3.2 if, at the time of
such request, the filing of such Form S-3 Registration Statement would, as
determined in good faith by a majority of the Board, be seriously detrimental to
3-DP or its stockholders or adversely affect a material financing project or a
material proposed or pending acquisition, merger or other

                                       10
<PAGE>

similar corporate transaction to which 3-DP is or imminently expects to be a
party, in which case registration shall take place as soon as practicable
thereafter, provided that such right of 3-DP to delay a request for registration
may be exercised by 3-DP not more than once in any one-year period.

          6.3.3 Piggyback Registration. Subject to the Preferential Registration
                ----------------------
Rights, if 3-DP at any time proposes to register any of its securities under the
Securities Act (other than a registration effected on either Form S-4 or S-8, or
similar or successor forms) for the purpose of selling such securities to the
public whether for its own account or for the account of any of its security
holders or both, 3-DP shall each such time promptly give written notice within a
30 days to Schering of its intention so to do. Upon the written request of
Schering given within 15 days after receipt of such notice (which request shall
state the number of Registerable Securities to be disposed of by Schering and,
if such offering is not underwritten, the intended method of disposition of such
Registerable Securities by Schering), 3-DP will use its best efforts to cause
promptly all Registerable Securities for which registration or qualification is
requested under the Securities Act or any other applicable federal or state law
or regulation so as to permit the sale or other disposition thereof in
accordance with Schering's written request. If the registration is to be
effected in connection with an underwritten offering,

                6.3.3.(a) Schering shall be required to sell the Registerable
Securities through the underwriter(s);

                6.3.3.(b) Schering (together with 3-DP) shall enter into an
underwriting agreement with the managing underwriter in the form customarily
used by such underwriter, which is reasonably acceptable to Schering; and

                6.3.3.(c) if the managing underwriter thereof determines that
the total number of shares of the Common Stock to be sold in such offering
should be limited due to market conditions, subject to the Preferential
Registration Rights, the reduction in the total number of shares offered shall
be made by first excluding any shares of selling stockholders who are not
holders of contractual rights to have such shares registered under the
Securities Act, and then, if necessary, by excluding pro rata (based on the
number of shares to be registered by each of such security holders) the
Registerable Securities to be sold by Schering and the holders of other
contractual rights to have such shares registered pursuant to agreements
comparable to this Section 6.3.3 before any reduction is made in the total
number of shares to be sold pursuant thereto by 3-DP and any holders of
Preferential Registration Rights.

     6.4  Registration Procedures.
          -----------------------

                                       11
<PAGE>

          6.4.1 The Company shall pay all Registration Expenses (as hereinafter
defined) in connection with any registration, qualification or compliance
hereunder, and Schering shall pay all Selling Expenses (as hereinafter defined).
"Registration Expenses" shall mean all expenses, except for Selling Expenses,
incurred by 3-DP in complying with the registration provisions of this
Agreement, including without limitation all federal and state registration,
qualification and filing fees, printing expenses, escrow fees, fees and
disbursements of counsel for 3-DP, blue sky fees and expenses and the expense of
any special audits incident to or required by any such registration. "Selling
Expenses" shall mean all selling commissions, underwriting fees and stock
transfer taxes applicable to the Registerable Securities and all fees and
disbursements of counsel for Schering.

          6.4.2 Whenever required under Article 6.3 to effect the registration
of any Registerable Securities, 3-DP will promptly: (i) prepare and file with
the Commission a registration statement and such amendments and supplements to
the registration statement and the prospectus used in connection with the
registration statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of the Registerable Securities
and keep such registration statement effective until the securities covered by
such registration statement have been sold, but in no event longer than 180 days
(subject to the right and obligation of 3-DP to promptly advise the selling
stockholder of applicable periods when the prospectus is not current and,
therefore, may not be used, in which case 3-DP covenants to use its reasonable
efforts to promptly take such actions necessary to permit sale thereunder); (ii)
furnish such number of prospectuses and other documents incident thereto,
including any amendment of or supplement to the prospectus, as Schering from
time to time may reasonably request; (iii) provide a transfer agent and
registrar for all Registerable Securities registered pursuant to the
registration statement and a CUSIP number for all such Registerable Securities,
in each case not later than the effective date of such registration; and (iv)
file the documents required of 3-DP and otherwise use its best efforts to
maintain requisite blue sky clearance in (A) all jurisdictions in which any of
the Registerable Securities is originally sold and (B) all other states
specified in writing by Schering, provided as to clause (B), however, that 3-DP
shall not be required to qualify to do business or consent to service of process
in any state in which it is not now so qualified or has not so consented.

          6.4.3 Schering shall furnish to 3-DP such information regarding it and
the distribution proposed by it as 3-DP may reasonably request in writing and as
shall be reasonably required in connection with any registration, qualification
or compliance described herein. Schering shall represent that such information
is true and complete in all material respects.

     6.5  Expiration of Registration Rights. Notwithstanding anything to the
          ---------------------------------
contrary contained herein, the registration rights granted hereunder and 3-DP's
obligations under this Section 6 will expire upon the expiration of the two-year
period commencing 12 months after the IPO Effective Date.

     6.6  Indemnification and Contribution.
          --------------------------------

                                       12
<PAGE>

          6.6.1 The Company agrees to indemnify and hold harmless Schering and
its successors, assigns, officers, directors, employees, stockholders, agents
and affiliates from and against any losses, claims, damages or liabilities (or
actions or proceedings in respect thereof) to which Schering may become subject
(under the Securities Act or otherwise) insofar as such losses, claims, damages
or liabilities (or actions or proceedings in respect thereof) arise out of, or
are based upon, any claim by a third party, including any governmental agency,
asserting any untrue statement of a material fact or omission of a material fact
contained in a registration statement, on the effective date thereof, or arise
out of any failure by 3-DP to fulfill any undertaking included in such
registration statement, including but not limited to 3-DP's duty to update, and
3-DP will, as incurred, reimburse Schering for any damages or legal or other
expenses reasonably incurred in investigating, defending or preparing to defend
any such action, proceeding or claim; provided, however, that 3-DP shall not be
                                      --------  -------
liable in any such case to the extent that such loss, claim, damages or
liability arises out of, or is based upon (i) an untrue statement made in such
registration statement in reliance upon and in conformity with information
furnished to 3-DP by Schering or an affiliate for use in preparation of such
registration statement or (ii) any untrue statement in any prospectus that is
corrected in any subsequent prospectus that was delivered to Schering prior to
the pertinent sale or sales by Schering.

          6.6.2 Schering agrees to indemnify and hold harmless 3-DP and its
successors, assigns, officers, directors, employees, stockholders, agents and
affiliates from and against any losses, claims, damages or liabilities (or
actions or proceedings in respect thereof) to which 3-DP may become subject
(under the Securities Act or otherwise) insofar as such losses, claims, damages
or liabilities (or actions or proceedings in respect thereof) arise out of, or
are based upon any claim by a third party asserting (i) an untrue statement made
in such registration statement in reliance upon and in conformity with
information furnished to 3-DP by Schering or an affiliate of Schering for use in
preparation of such registration statement, provided that Schering shall not be
liable in any such case for (i) any untrue statement included in any prospectus
which statement has been corrected, in writing, by Schering and delivered to
3-DP before the sale from which such loss occurred or (ii) any untrue statement
in any prospectus that is corrected in any subsequent prospectus that was
delivered to Schering prior to the pertinent sale or sales by Schering, and
Schering will, as incurred, reimburse 3-DP for any legal or other expenses
reasonably incurred in investigating, defending or preparing to defend any such
action, proceeding or claim.

          6.6.3 Promptly after receipt by any indemnified person of a notice of
a claim or the beginning of any action in respect of which indemnity is to be
sought against an indemnifying person pursuant to this Section 6.6, such
indemnified person shall notify the indemnifying person in writing of such claim
or of the commencement of such action, and, subject to the provisions
hereinafter stated, in case any such action shall be brought against an
indemnified person and the indemnifying person shall have been notified thereof,
the indemnifying person shall be entitled to participate therein, and, to the
extent that it shall wish, to assume the defense thereof, with counsel
reasonably satisfactory to the indemnified person.

                                       13
<PAGE>

After notice from the indemnifying person to such indemnified person of the
indemnifying person's election to assume the defense thereof, the indemnifying
person shall not be liable to such indemnified person for any legal expenses
subsequently incurred by such indemnified person in connection with the defense
thereof, provided that if there exists or shall exist a conflict of interest
that would make it inappropriate in the reasonable judgment of the indemnified
person for the same counsel to represent both the indemnified person and such
indemnifying person or any affiliate or associate thereof, the indemnified
person shall be entitled to retain its own counsel at the expense of such
indemnifying person.

     The obligations of 3-DP and Schering under this Section 6 shall be in
addition to any liability which 3-DP and Schering may otherwise have.

          6.6.4 If the indemnification provided for in this Section 6.6 is held
by a court of competent jurisdiction to be unavailable to an indemnified party
with respect to any lose, liability, claim, damage or expense referred to
herein, then the indemnifying party, in lieu of indemnifying such indemnified
party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage or expense
in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense, as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties, relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.

     6.7  Transfer of Registration Rights. The right to sell Registrable
          -------------------------------
Securities pursuant to a registration statement described herein may not be
assigned or transferred by Schering other than to an entity that directly or
indirectly controls or is controlled by or under common control with Schering.

     6.8  Lock-Up Upon IPO. Schering agrees that, in the event 3-DP proposes to
          ----------------
conduct an IPO at a time at which Schering beneficially owns 3-DP's Common
Stock, Schering will agree to be a party and subject to any lock-up agreement
proposed by the managing underwriter(s) for the IPO with respect to the sale,
transfer, conversion or other disposition of the Registrable Securities, which
lock-up agreement will contain no more restrictive terms and conditions than
those to which 3-DP's then current directors, officers and stockholders who
beneficially own 5% or greater of the Common Stock will be subject in connection
therewith and in no event shall the period of such lock-up exceed 180 days from
the effective date of the IPO.

7.   Filings and Authorizations. 3-DP and Schering, as promptly as practicable,
     --------------------------
(a) will make, or cause to be made, all filings and submissions under laws,
rules and regulations applicable to them as may be required for them to
consummate the transactions contemplated hereby in accordance with the terms of
this Agreement, and (b) will use reasonable efforts to obtain, or

                                       14
<PAGE>

cause to be obtained, all authorizations, approvals, consents and waivers from
all governmental authorities necessary to be obtained by them in order for them
so to consummate such transactions.

8.   Conditions to Obligation of Each Party to Effect the Transactions
     -----------------------------------------------------------------
Contemplated by this Agreement. The obligation of each party to effect the
------------------------------
transactions contemplated by this Agreement shall be subject to the fulfillment
at or prior to the Closing of the following conditions:

     8.1 all governmental and other consents and approvals, if any, necessary to
permit the consummation of the transactions contemplated by this Agreement shall
have been obtained; and

     8.2 no stop order or other order enjoining the sale of the Series D
Preferred Shares to be purchased and sold at the Closing shall have been issued
and no proceedings for such purpose shall be pending or, to the knowledge of
3-DP, threatened by the Commission or any commissioner of corporations or
similar officer of any state having jurisdiction over this transaction, and no
preliminary or permanent injunction or other order, decree or ruling issued by a
court of competent jurisdiction or by a governmental, regulatory or
administrative agency or commission nor any statute, rule, regulation or
executive order promulgated or enacted by any governmental authority shall be in
effect that would restrain or otherwise prevent the consummation of the
transactions contemplated by this Agreement.

9.   Conditions to Schering's Obligations.
     ------------------------------------

     9.1  Closing. The obligations of Schering under this Agreement to purchase
          -------
the Series D Preferred Shares to be purchased pursuant to Section 2.2 of this
Agreement are subject to the fulfillment on or before the Closing of each of the
following conditions by 3-DP, the waiver of which shall not be effective without
the consent of Schering thereto:

          9.1.1 Representations and Warranties. The representations and
                ------------------------------
warranties of 3-DP contained in Section 4 shall be true and correct on and as of
the Closing Date with the same effect as though such representations and
warranties had been made on and as of the Closing Date.

          9.1.2 Performance. 3-DP shall have performed and complied in all
                -----------
material respects with all agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by it on or
before the Closing, and all corporate or other proceedings in connection with
the transactions contemplated at the Closing and all documents incident thereto
shall be reasonably satisfactory in form and in substance to Schering.

          9.1.3 Compliance Certificate. An officer of 3-DP shall have delivered
                ----------------------
to Schering a certificate certifying that the conditions specified in Sections
9.1.1 and 9.1.2 have been fulfilled.

                                       15
<PAGE>

          9.1.4 The License Agreement. 3-DP and Schering AG shall have entered
                ---------------------
into the License Agreement.

          9.1.5 Opinion of Company Counsel. Schering shall have received an
                --------------------------
opinion from Morgan, Lewis & Bockius LLP, counsel to 3-DP, dated as of the
Closing Date, in substantially the form of Exhibit 9.1.5.
                                           -------------

          9.1.6 Certificate. 3-DP shall have furnished to Schering a
                -----------
certificate, signed by an authorized officer of 3-DP, certifying: (i) the due
organization and good standing of 3-DP; (ii) the corporate resolutions of 3-DP
authorizing the transactions contemplated by this Agreement; and (iii) the
incumbency of officers of 3-DP executing this Agreement and the other
instruments or certificates delivered upon the Closing.

          9.1.7 Share Certificate. 3-DP shall have furnished to Schering a
                -----------------
certificate or certificates representing the Series D Preferred Shares to be
purchased and sold at the Closing pursuant to Section 2.2 (free and clear of all
liens, claims and other encumbrances except as otherwise provided herein).

          9.1.8 Restated Certificate. 3-DP shall have adopted and filed with the
                --------------------
Secretary of State of Delaware the Restated Certificate on or before the
Closing.

          9.1.9 Consents. 3-DP shall have furnished to Schering a copy of the
                --------
signed consents a waiver of preemptive rights from other holders of 3-DP stock
that are necessary to consummate the issuance of the Securities.

          9.1.10 No Conflict. No statute, rule, regulation, executive order,
                 -----------
decree, temporary restraining order, preliminary or permanent injunction or
other order enacted, entered, promulgated, enforced or issued by any applicable
governmental entity or other legal restraint or prohibition preventing the
acquisition of the Securities shall be in effect.

          9.1.11 Other Documentation. 3-DP shall have furnished to Schering such
                 -------------------
other instruments and documents, in form and substance reasonably acceptable to
Schering, as may be necessary to effect the Closing.

10.  Conditions to 3-DP's Obligations.
     --------------------------------

     10.1 Closing. The obligations of 3-DP under this Agreement to sell the
     ------------
Series D Preferred Shares to be sold pursuant to Section 2.2 of this Agreement
are subject to the fulfillment on or before the Closing of each of the following
conditions by Schering, the waiver of which shall not be effective without the
consent of 3-DP thereto:

          10.1.1 Representations and Warranties. The representations and
                 ------------------------------
warranties of Schering contained in Section 5 shall be true on and as of the
Closing Date with the same effect as though such representations and warranties
had been made on and as of the Closing Date.

                                       16
<PAGE>

          10.1.2 Performance. Schering shall have performed and complied in all
                 -----------
material respects with all agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by it on or
before the Closing, and all corporate or other proceedings in connection with
the transactions contemplated at the Closing and all documents incident thereto
shall be reasonably satisfactory in form and in substance to 3-DP.

          10.1.3 Compliance Certificate. An officer of Schering shall have
                 ----------------------
delivered to 3-DP a certificate certifying that the conditions specified in
Sections 10.1.1 and 10.1.2 have been fulfilled.

          10.1.4 Payment of Purchase Price. Schering shall have delivered the
                 -------------------------
purchase price required to be paid at the Closing.

          10.1.5 License Agreement. 3-DP and Schering AG shall have entered into
                 -----------------
the License Agreement.

          10.1.6 Other Documentation. Schering shall have furnished to 3-DP such
                 -------------------
other instruments and documents, in form and substance reasonably acceptable to
3-DP, as may be necessary to effect the Closing.

11.  Covenants. 3-DP covenants and agrees that prior to the consummation of
     ---------
3-DP's IPO and so long as Schering shall own any Securities, it will perform and
observe the following covenants and provisions:

     11.1 Corporate Existence. Do or cause to be done all things necessary to
          -------------------
preserve, renew and keep in full force and effect its legal existence.

     11.2 Reporting Requirements. Furnish to Schering:
          ----------------------

          11.2.1 Monthly Reports: as soon as available and in any event within
                 ---------------
45 days after the end of each calendar month, balance sheets, statements of
income and retained earnings and a summary statement of monthly cash flow and
expenses of 3-DP and its subsidiaries for such month and for the period
commencing at the end of the previous fiscal year and ending with the end of
such month, setting forth in each case in comparative form the corresponding
figures for the corresponding period of the preceding fiscal year, and including
comparisons to the monthly budget and an analysis of the variances from the
budget or plan, prepared in accordance with generally accepted accounting
principles consistently applied, subject to year-end audit adjustment.

          11.2.2 Annual Reports: as soon as available, a copy of the annual
                 --------------
audit report for such year for 3-DP and its subsidiaries, including therein
consolidated and consolidating balance sheets of 3-DP and its subsidiaries as of
the end of such fiscal year and consolidated and consolidating statements of
income and retained earnings and of changes in financial position of 3-DP and
its subsidiaries for such fiscal year, setting forth in each case in comparative
form the corresponding figures for the preceding fiscal year, all such
consolidated statements to be duly

                                       17
<PAGE>

certified by an independent public accountant of recognized national standing
approved by the Board of Directors.

          11.2.3 Notice of Adverse Changes: promptly after the occurrence
                 -------------------------
thereof and in any event within 15 Business Days after it becomes aware of each
occurrence, notice of any material adverse change in the business, operations,
properties, assets, prospects or condition (financial or otherwise) of 3-DP.

12.  Miscellaneous.
     -------------

     12.1 Expenses. 3-DP and Schering shall each pay its own expenses incurred
          --------
in connection with the negotiation, execution and performance of this Agreement.

     12.2 Waivers and Amendments. With the written consent of 3-DP and the
          ----------------------
record holders of more than fifty percent of the Securities then outstanding,
the terms of this Agreement may be waived or amended.

     12.3 Governing Law. This Agreement shall be governed in all respects by the
          -------------
laws of the State of New York without giving effect to the conflicts of law
provisions thereof.

     12.4 Survival. The representations, warranties, covenants and agreements
          --------
made herein and in any certificate delivered pursuant hereto shall survive any
investigation made by 3-DP or Schering and the Closing.

     12.5 Successors and Assigns. The provisions hereof shall inure to the
          ----------------------
benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties hereto (specifically including successors in
interest to Securities).

     12.6 Entire Agreement. This Agreement constitutes the full and entire
          ----------------
understanding and agreement between the parties with regard to the subject
hereof.

     12.7 Notices, etc. All notices and other communications required or
          -------------
permitted hereunder shall be effective upon receipt and shall be in writing and
may be delivered in person, overnight delivery service or U.S. mail, in which
event it may be mailed by first-class, certified or registered, postage prepaid,
addressed (a) if to Schering, at P.O. Box 1000, Montville, New Jersey 07045-1000
Attention General Counsel or at such other address as Schering shall have
furnished to 3-DP in writing, with a copy to Cravath, Swaine & Moore, Worldwide
Plaza, 825 Eighth Avenue, New York, NY 10019-7475, attention: Peter S. Wilson,
facsimile: 212-474-3700, or (b) if to 3-DP, at its address set forth at the
beginning of this Agreement, attention: Scott Horvitz, facsimile: 610-458-8258,
or at such other address as 3-DP shall have furnished to Schering in writing.

     12.8 Severability of this Agreement. If any provision of this Agreement
          ------------------------------
shall be judicially determined to be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

                                       18
<PAGE>

     12.9 Titles and Subtitles. The titles of the paragraphs and subparagraphs
          --------------------
of this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement.

     12.10 Counterparts. This Agreement may be executed in any number of
           ------------
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.

     12.11 Publicity. 3-DP, Schering AG and Schering shall not originate any
           ---------
written publicity, news release, or other announcement or statement relating to
this Agreement (the "Written Disclosure") without the prior prompt review and
written approval of the other party, which approval shall not be unreasonably
withheld or delayed. Notwithstanding the foregoing provisions of this Section
12.11, any party may make any public Written Disclosure it believes in good
faith based upon the advice of counsel is required by applicable law or any
listing or trading agreement concerning its publicly traded securities, provided
that prior to making such Written Disclosure, the disclosing party shall provide
the other party with a copy of the materials proposed to be disclosed and
provide the receiving party with at least two (2) business days to review the
proposed Written Disclosure.

                                       19
<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed and delivered by their proper and duly authorized officers as of the
day and year first written above.

                                    3-DIMENSIONAL PHARMACEUTICALS, INC.

                                    By:/s/ David C. U'Prichard
                                       -------------------------------------
                                         David C. U'Prichard

                                    SCHERING BERLIN VENTURE CORPORATION

                                    By:/s/ Illegible
                                       -------------------------------------
                                          Name:
                                          Title:

                                       20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}]]